Targeted Radionuclide Therapy of Human Tumors
Open accessAbstract
Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic therapy of cancer. The methods of targeted radionuclide therapy are based on the use of molecular carriers of radionuclides with high affinity to antigens on the surface of tumor cells. The potential of targeted radionuclide therapy has markedly grown nowadays due to the expanded knowledge base in cancer biology, bioengineering, and radiochemistry. In this review, progress in the radionuclide therapy of hematological malignancies and approaches for treatment of solid tumors is addressed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Targeted radionuclide therapy enhances treatment efficacy while minimizing damage to healthy tissues, improving patient outcomes.
“This approach enhances treatment efficacy while minimizing damage to healthy tissues, ultimately improving patient outcomes [3].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [3]
The Abstract says targeted radionuclide therapy causes less collateral damage to normal tissues than external beam therapy, and the Conclusions describe an overall increase in therapeutic efficiency. But the Conclusions limit demonstrated therapeutic outcomes to hematological malignancies and say efficacy against solid tumors remains low, so the unqualified claim of improved patient outcomes goes beyond the source. (LLM, conf=0.86)
Experimental — accuracy not yet measuredTargeted radionuclide therapy delivers radioactive payloads to diseased tissues.
“Beyond diagnostics, radiopharmaceuticals are integral to targeted radionuclide therapy, a precise method of delivering radioactive payloads to diseased tissues.”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · see citing works
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,167 · see citing works
Ward, J. F. (1988) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60611-x · Cited by 1,499 · see citing works
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179 · see citing works
Cloning and characterization of the thyroid iodide transporter
Dai, G., Levy, O., & Carrasco, N. (1996) · Nature · doi:10.1038/379458a0 · Cited by 1,109 · see citing works
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3930 · Cited by 717 · see citing works
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N. V., & Press, O. W. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3925 · Cited by 540 · see citing works
Radiotherapy and Immunogenic Cell Death
Golden, E. B., & Apétoh, L. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.005 · Cited by 463 · see citing works
Morschhauser, F., Radford, J. A., Hoof, A. V., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d’Amore, F., González, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2015 · Cited by 459 · see citing works
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr, C., Pless, M., Maëcke, H. R., et al. (2002) · PubMed · Cited by 446 · see citing works
Tagawa, S. T., Milowsky, M. I., Morris, M. J., Vallabhajosula, S., Christos, P. J., Akhtar, N. H., Osborne, J. R., Goldsmith, S. J., Larson, S. M., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427 · see citing works
Bruland, Ø. S., Nilsson, S. F., Fisher, D. R., & Larsen, R. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0841 · Cited by 356 · see citing works
Radiobiologic principles in radionuclide therapy.
Kassis, A. I., & Adelstein, S. J. (2005) · PubMed · Cited by 265 · see citing works
Barendsen, G. W., Beusker, T. L. J., Vergroesen, A. J., et al. (1960) · Radiation Research · doi:10.2307/3570859 · Cited by 255 · see citing works
Therapeutic radionuclides in nuclear medicine: current and future prospects
Yeong, C. H., Cheng, M., & Ng, K.-H. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400131 · Cited by 240 · see citing works
Introduction to Radiobiology of Targeted Radionuclide Therapy
Pouget, J., Lozza, C., Deshayes, E., Boudousq, V., & Navarro‐Teulon, I. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00012 · Cited by 233 · see citing works
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma
Leonard, J. P., Coleman, M., Ketas, J. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0294 · Cited by 227 · see citing works
Press, O. W., Shan, D., Howell-Clark, J., Eary, J. F., Appelbaum, F. R., Matthews, D. C., King, D. J., Haines, A. M. R., Hamann, P., Hinman, L. M., et al. (1996) · PubMed · Cited by 211 · see citing works
Morschhauser, F., Radford, J. A., Hoof, A. V., Botto, B., Rohatiner, A. Z. S., Salles, G., Soubeyran, P., Tilly, H., Bischof-Delaloye, A., van Putten, W. L. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6400 · Cited by 204 · see citing works
Astatine-211: Production and Availability
Zalutsky, M. R., & Pruszyński, M. (2011) · Current Radiopharmaceuticals · doi:10.2174/1874471011104030177 · Cited by 200 · see citing works
Vose, J. M., Carter, S., Burns, L. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9453 · Cited by 173 · see citing works
Press, O. W., Unger, J. M., Rimsza, L. M., Friedberg, J. W., LeBlanc, M. L., Czuczman, M. S., Kaminski, M. S., Braziel, R. M., Spier, C. M., Gopal, A. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4101 · Cited by 172 · see citing works
Radioimmunotherapy of Lymphoma: Bexxar and Zevalin
Goldsmith, S. J. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.11.002 · Cited by 172 · see citing works
Monoclonal antibodies in acute lymphoblastic leukemia
Jabbour, E. J., O'Brien, S. M., Ravandi, F., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-08-596403 · Cited by 162 · see citing works
Anti-cancer therapies targeting the tumor stroma
Hofmeister, V., Schrama, D., & Becker, J. C. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0365-5 · Cited by 155 · see citing works
Therapeutic radionuclides and nuclear data
Qaim, S. M. (2001) · Radiochimica Acta · doi:10.1524/ract.2001.89.4-5.297 · Cited by 145 · see citing works
Liersch, T., Meller, J., Kulle, B., Behr, T. M., Markus, P. M., Langer, C., Ghadimi, Β. M., Wegener, W. A., Kovacs, J., Horak, I. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.622 · Cited by 134 · see citing works
Beatson, R., Taylor‐Papadimitriou, J., & Burchell, J. (2010) · Immunotherapy · doi:10.2217/imt.10.17 · Cited by 125 · see citing works
Targeted Radionuclide Therapy - An Overview
Dash, A. K., Knapp, F. F., & Pillai, M. (2013) · Current Radiopharmaceuticals · doi:10.2174/18744710113066660023 · Cited by 124 · see citing works
Gudkov, S. V., Shtarkman, I. N., Smirnova, V., Черников, А. В., & Брусков, В. И. (2006) · Radiation Research · doi:10.1667/rr3552.1 · Cited by 119 · see citing works
Self-citationSansovini, M., Severi, S., Ambrosetti, A., Monti, M., Nanni, O., Sarnelli, A., Bodei, L., Garaboldi, L., Bartolomei, M., & Paganelli, G. (2013) · Neuroendocrinology · doi:10.1159/000348394 · Cited by 114 · see citing works
Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid
Seidlin, S. M., Marinelli, L. D., & Oshry, E. (1990) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.40.5.299 · Cited by 114 · see citing works
Raja, C., Graham, P., Rizvi, S. M., Song, E. Y., Goldsmith, H., Thompson, J. F., Bosserhoff, A., Morgenstern, A., Apostolidis, C., Kearsley, J. H., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.6.4089 · Cited by 110 · see citing works
Multifunctional nanoparticles for use in theranostic applications
Cole, J. T., & Holland, N. B. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0218-2 · Cited by 108 · see citing works
Pretargeted Molecular Imaging and Radioimmunotherapy
Goldenberg, D. M., Chang, C., Rossi, E. A., McBride, W. J., & Sharkey, R. M. (2012) · Theranostics · doi:10.7150/thno.3582 · Cited by 108 · see citing works
Garin‐Chesa, P., Sakamoto, J., Welt, S., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.3.465 · Cited by 99 · see citing works
Rhenium-188: Availability from the 188W/188Re Generator and Status of Current Applications
Pillai, M. R. A., Dash, A. K., & Knapp, F. F. R. (2012) · Current Radiopharmaceuticals · doi:10.2174/1874471011205030228 · Cited by 98 · see citing works
Pandit-Taskar, N. D., Larson, S. M., & Carrasquillo, J. A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112482 · Cited by 95 · see citing works
Allen, B., Singla, A. A., Rizvi, S. M. A., Graham, P., Bruchertseifer, F., Apostolidis, C., & Morgenstern, A. (2011) · Immunotherapy · doi:10.2217/imt.11.97 · Cited by 93 · see citing works
Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
Forrer, F., Waldherr, C., Maëcke, H. R., et al. (2006) · PubMed · Cited by 91 · see citing works
Ocean, A. J., Pennington, K. L., Guarino, M. J., Sheikh, A., Bekaii‐Saab, T., Serafini, A. N., Lee, D. C., Sung, M. W., Güleç, S., Goldsmith, S. J., et al. (2012) · Cancer · doi:10.1002/cncr.27592 · Cited by 84 · see citing works
Radioimmunotherapy with α-Particle-Emitting Radionuclides
Seidl, C. (2014) · Immunotherapy · doi:10.2217/imt.14.16 · Cited by 79 · see citing works
Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
Erba, P. A., Sollini, M., Orciuolo, E., Traino, C., Petrini, M., Paganelli, G., Bombardieri, E., Grana, C. M., Giovannoni, L., Neri, D., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101006 · Cited by 77 · see citing works
Huang, S.-Y., Bolch, W. E., Lee, C., Brocklin, H. F. V., Pampaloni, M. H., Hawkins, R. A., Sznewajs, A., DuBois, S. G., Matthay, K. K., & Seo, Y. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0783-7 · Cited by 76 · see citing works
Normal tissue radiosensitivity — How important is it?
Burnet, N. G., Wurm, R. E., Nyman, J., & Peacock, J. H. (1996) · Clinical Oncology · doi:10.1016/s0936-6555(05)80035-4 · Cited by 75 · see citing works
Radioimmunoconjugates for the Treatment of Cancer
Kraeber‐Bodéré, F., Bodet‐Milin, C., Rousseau, C., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.07.004 · Cited by 71 · see citing works
DuBois, S. G., Groshen, S. G., Park, J. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3240 · Cited by 71 · see citing works
Zhou, M. J., Doral, M. Y., DuBois, S. G., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.023 · Cited by 67 · see citing works
Nicola, J. P., Nazar, M., Mascanfroni, I. D., Pellizas, C. G., & Masini-Repiso, A. M. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0102 · Cited by 67 · see citing works
Tomblyn, M. B. (2012) · Cancer Control · doi:10.1177/107327481201900208 · Cited by 65 · see citing works
Toohey, R. E., Stabin, M. G., & Watson, E. E. (2000) · RadioGraphics · doi:10.1148/radiographics.20.2.g00mc33533 · Cited by 65 · see citing works
Güleç, S. A., Cohen, S. J., Pennington, K. L., Zuckier, L. S., Hauke, R. J., Horne, H. B., Wegener, W. A., Teoh, N., Gold, D. V., Sharkey, R. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2579 · Cited by 63 · see citing works
Radium-223 in the Treatment of Osteoblastic Metastases: A Critical Clinical Review
Humm, J. L., Sartor, O. A., Parker, C. C., Bruland, Ø. S., & Macklis, R. M. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.12.061 · Cited by 61 · see citing works
Quach, A., Ji, L., Mishra, V., Sznewajs, A., Veatch, J., Huberty, J., Franc, B., Sposto, R., Groshen, S., Wei, D., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22767 · Cited by 60 · see citing works
A pretargeting system for tumor PET imaging and radioimmunotherapy
Kraeber‐Bodéré, F., Rousseau, C., Bodet‐Milin, C., Frampas, É., Faivre-Chauvet, A., Rauscher, A., Sharkey, R. M., Goldenberg, D. M., Chatal, J., & Barbet, J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00054 · Cited by 57 · see citing works
New Antibody Conjugates in Cancer Therapy
Govindan, S. V., & Goldenberg, D. M. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.191 · Cited by 56 · see citing works
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
Bodei, L., Cremonesi, M., Kidd, M. S., et al. (2014) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2014.04.005 · Cited by 56 · see citing works
Strosberg, J., Wolin, E. M., Chasen, B., Kulke, M. H., Bushnell, D. L., Caplin, M. E., Baum, R. P., Mittra, E., Hobday, T. J., Hendifar, A., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31929-3 · Cited by 56 · see citing works
Radiation Biology: A Handbook for Teachers and Students
Khaled, S., & Held, K. D. (2012) · International Journal of Radiation Biology · doi:10.3109/09553002.2012.666006 · Cited by 56 · see citing works
The importance of sodium/iodide symporter (NIS) for thyroid cancer management
Carvalho, D. P., & Ferreira, A. C. F. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000500004 · Cited by 53 · see citing works
Anderson, P. M., Subbiah, V., & ROHREN, E. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_16 · Cited by 52 · see citing works
Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma
Chung, J.-K., Youn, H. W., Kang, J. H., et al. (2010) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-009-0016-1 · Cited by 50 · see citing works
Advances in Anticancer Radiopharmaceuticals
Jackson, M. R., Falzone, N., & Vallis, K. A. (2013) · Clinical Oncology · doi:10.1016/j.clon.2013.06.004 · Cited by 49 · see citing works
Gudkov, S. V., Gudkova, O. Y., Chernikov, A. V., et al. (2009) · International Journal of Radiation Biology · doi:10.1080/09553000802641144 · Cited by 48 · see citing works
Self-citationZhang, M., Yao, Z., Zhang, Z., Garmestani, K., Talanov, V. S., Plascjak, P. S., Yu, S. G., Kim, H., Goldman, C. K., Paik, C. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1189 · Cited by 47 · see citing works
Seo, Y., Gustafson, W. C., Dannoon, S. F., Nekritz, E. A., Lee, C.-L., Murphy, S. T., VanBrocklin, H. F., Hernandez‐Pampaloni, M., Haas-Kogan, D. A., Weiss, W. A., et al. (2012) · Molecular Imaging and Biology · doi:10.1007/s11307-012-0552-4 · Cited by 45 · see citing works
Iodine‐131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective
Kayano, D., & Kinuya, S. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/189135 · Cited by 44 · see citing works
[Radioprotectors: History, Trends and Prospects].
Gudkov, S. V., Popova, N. R., & Брусков, В. И. (2015) · PubMed · Cited by 44 · see citing works
Self-citationRadioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
Chung, J.-K., & Cheon, G. J. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.3.233 · Cited by 43 · see citing works
Seifert, R. P., Bulkeley, W., Zhang, L., et al. (2014) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2014.06.001 · Cited by 42 · see citing works
Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review
Nisa, L., Savelli, G., & Giubbini, R. (2010) · Annals of Nuclear Medicine · doi:10.1007/s12149-010-0444-0 · Cited by 41 · see citing works
Press, O. W., Unger, J. M., Rimsza, L. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1120 · Cited by 41 · see citing works
Hdeib, A. M., & Sloan, A. E. (2012) · Future Oncology · doi:10.2217/fon.12.58 · Cited by 40 · see citing works
HLA class II antibodies in the treatment of hematologic malignancies
Dechant, M., Bruenke, J., & Valerius, T. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00252-5 · Cited by 39 · see citing works
Radioprotective substances: History, trends and prospects
Gudkov, S. V., Popova, N. R., & Брусков, В. И. (2015) · BIOPHYSICS · doi:10.1134/s0006350915040120 · Cited by 35 · see citing works
Self-citationRadioimmunodiagnosis and radioimmunotherapy, 1982.
Sfakianakis, G. N., & DeLand, F. H. (1982) · PubMed · Cited by 33 · see citing works
Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case
Ronca, R., Sozzani, S., Presta, M., & Alessi, P. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.06.005 · Cited by 31 · see citing works
Anti-CD30 antibody–based therapy
Koon, H. B., & Junghans, R. P. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200011000-00012 · Cited by 28 · see citing works
Optimizing radioimmunoconjugate delivery in the treatment of solid tumor
Huang, C., Pourgholami, M. H., & Allen, B. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.005 · Cited by 28 · see citing works
Effective use of strontium-89 in osseous metastases
Kuroda, I. (2011) · Annals of Nuclear Medicine · doi:10.1007/s12149-011-0560-5 · Cited by 27 · see citing works
Radioimmunotherapy of malignancies.
REILLY, R. M. (1991) · PubMed · Cited by 27 · see citing works
New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Maffioli, L. S., Florimonte, L., Costa, D. C., Castanheira, J. C., Grana, C. M., Luster, M., Bodei, L., & Chinol, M. (2015) · PubMed · Cited by 26 · see citing works
Radiolabeled Apoptosis Imaging Agents for Early Detection of Response to Therapy
Ogawa, K., & Aoki, M. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/732603 · Cited by 25 · see citing works
Antioxidative and Radiation Modulating Properties of Guanosine-5′-Monophosphate
Asadullina, N. R., Usacheva, A., Смирнов, В. С., et al. (2010) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2010.518576 · Cited by 25 · see citing works
Trieu, M., DuBois, S. G., Pon, E., Nardo, L., Hawkins, R. A., Marachelian, A., Twist, C. J., Park, J. R., & Matthay, K. K. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25816 · Cited by 24 · see citing works
Peptides for Diagnosis and Treatment of Colorectal Cancer
Shapira, S., Fokra, A., Arber, N., et al. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140205134616 · Cited by 24 · see citing works
Transcriptional Regulation of Human Sodium/Iodide Symporter Gene: A Role for Redox Factor-1
Puppin, C., Arturi, F., Ferretti, E., et al. (2003) · Endocrinology · doi:10.1210/en.2003-1250 · Cited by 23 · see citing works
Targeted radionuclide therapies for pancreatic cancer
Shah, M., Silva, R. D., Gravekamp, C., Libutti, S. K., Abraham, T., & Dadachova, E. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.32 · Cited by 21 · see citing works
Han, S., Jin, G., Wang, L., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/268479 · Cited by 20 · see citing works
Yttrium‐90 biodistribution by yttrium‐87 imaging: A theoretical feasibility analysis
Sgouros, G. (1998) · Medical Physics · doi:10.1118/1.598323 · Cited by 19 · see citing works
Biomarkers for immunotherapy in genitourinary malignancies
Slovin, S. F. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.02.007 · Cited by 18 · see citing works
Radioimmunotherapy for Hematopoietic Cell Transplantation
Jurcic, J. G. (2013) · Immunotherapy · doi:10.2217/imt.13.11 · Cited by 15 · see citing works
Fujiki, M., Aucejo, F., & Kim, R. (2012) · Clinical Transplantation · doi:10.1111/ctr.12042 · Cited by 14 · see citing works
Systemic targeted alpha radiotherapy for cancer.
Allen, B. (2013) · PubMed · Cited by 13 · see citing works
Systemic targeted alpha radiotherapy for cancer
Allen, B. (2012) · Journal and proceedings of the Royal Society of New South Wales · doi:10.5962/p.361662 · Cited by 11 · see citing works
Ruiz, A. C. S., de la Cruz‐Merino, L., & Provencio, M. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714532282 · Cited by 7 · see citing works
Guo, R., Zhang, R., Pan, Y., et al. (2011) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e328344a1ad · Cited by 6 · see citing works
CD5- and CD23-Positive Splenic Diffuse Large B-Cell Lymphoma with Very Low CD20 Expression
Tabata, R., Iwama, H., Tabata, C., et al. (2014) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.54.155 · Cited by 5 · see citing works
Short-Term Results of Combined Radioimmunotherapy in Inoperable Lung Cancer
Curcio, C. G., Vasile, C., Gianciotta, A., et al. (1976) · Tumori Journal · doi:10.1177/030089167606200602 · Cited by 5 · see citing works
Systemic Targeted Alpha Radiotherapy for Cancer - A Review
Allen, B. (2014) · Bangladesh Journal of Medical Physics · doi:10.3329/bjmp.v6i1.19755 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144 · see citing works
- Authors
- Gudkov, S., Shilyagina, N., Vodeneev, V., & Zvyagin, A.
- Affiliations
- Russian Academy of Sciences (RU)
- Laboratory of Optical Theranostics, Lobachevsky Nizhny Novgorod State University, Gagarin Ave. 23, Nizhny Novgorod 603950, Russia
- N. I. Lobachevsky State University of Nizhny Novgorod (RU)
- Corresponding author
- Gudkov, Sergey
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-12-28
- Volume
- 17
- Issue
- 1
- Pages
- 33
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4730279
- OpenAlex
- W2211363142
- Cited by
- 456
- References
- 101
- Citations by year
- 2026: 21 · 2025: 20 · 2024: 29 · 2023: 270 · 2022: 25 · 2021: 23 · 2020: 23 · 2019: 10 · 2018: 16 · 2017: 12 · 2016: 6 · 2015: 1
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Targeted Federal Program of the Ministry of Education and Science of The Russian Federation (14.578.21.0030 (RFMEFI57814X0030))
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Keywords
- targeted radionuclide therapy, tumor targeting, molecular carriers, tumor antigens, hematologic malignancies, solid tumors, metastasis, radiochemistry, cancer therapy
- MeSH terms
- Humans, Neoplasms, Radioimmunotherapy, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
